AR073917A1 - Sinergismo antibiotico - Google Patents
Sinergismo antibioticoInfo
- Publication number
- AR073917A1 AR073917A1 ARP090104058A ARP090104058A AR073917A1 AR 073917 A1 AR073917 A1 AR 073917A1 AR P090104058 A ARP090104058 A AR P090104058A AR P090104058 A ARP090104058 A AR P090104058A AR 073917 A1 AR073917 A1 AR 073917A1
- Authority
- AR
- Argentina
- Prior art keywords
- identity
- composition according
- staphylococcus aureus
- bacterial infection
- antibacterial compound
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 3
- 241000191967 Staphylococcus aureus Species 0.000 abstract 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000000541 Defensins Human genes 0.000 abstract 2
- 108010002069 Defensins Proteins 0.000 abstract 2
- 241000192125 Firmicutes Species 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229930186147 Cephalosporin Natural products 0.000 abstract 1
- 229930182555 Penicillin Natural products 0.000 abstract 1
- 241000295644 Staphylococcaceae Species 0.000 abstract 1
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 229940126575 aminoglycoside Drugs 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 229940124587 cephalosporin Drugs 0.000 abstract 1
- 150000001780 cephalosporins Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ULXTYUPMJXVUHQ-OVTFQNCVSA-N lipid II Chemical compound OC(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@@H](OP(O)(=O)OP(O)(=O)OC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ULXTYUPMJXVUHQ-OVTFQNCVSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 150000002960 penicillins Chemical class 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere al sinergismo antibiotico de composiciones farmacéuticas que comprenden una defensina y un antibiotico betalactámico. Reivindicacion 3: La composicion de acuerdo con la reivindicacion 2, en fa cual el primer y segundo compuesto antibacteriano exhibe un índice de FIC < o = 0,5 utilizando un organismo de prueba seleccionado entre el grupo integrado por Streptococcus pneumoniae ATCC49619, Staphylococcus aureus ATCC29213, Staphylococcus aureus ATCC34400, Staphylococcus aureus ATCC25923, y Staphylococcus epidermidis ATCC49134. Reivindicacion 4: La composicion de acuerdo con cualquiera de las reivindicaciones 1-3, en la cual el primer compuesto antibacteriano se une al precursor de la pared celular bacteriana Lípido l y/o Lípido II. Reivindicacion 8: La composicion de acuerdo con cualquiera de las reivindicaciones 1-7, en la cual la defensina comprende una secuencia de aminoácidos que tiene por lo menos 80% de identidad, con preferencia por lo menos 85% de identidad, con mayor preferencia por lo menos 90% de identidad, incluso con mayor preferencia por lo menos 95% de identidad, y muy preferentemente por lo menos 97% de identidad con la secuencia de aminoácidos de la SEC ID NO:1. Reivindicacion 9: La composicion de acuerdo con cualquiera de las reivindicaciones 1-8, en la cual el segundo compuesto antibacteriano se selecciona entre el grupo integrado por penicilinas, cefalosporinas y aminoglicosidos. Reivindicacion 11: El uso de una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-10 para la elaboracion de un medicamento para el tratamiento terapéutico de una infeccion bacteriana. Reivindicacion 12: El uso de acuerdo con la reivindicacion 11, en el cual la infeccion bacteriana es causada por bacterias Gram-positivas. Reivindicacion 15: El uso de acuerdo con la reivindicacion 14, en el cual la infeccion bacteriana es causada por bacterias Gram-positivas tales como Estreptococos o Estafilococos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08167451 | 2008-10-23 | ||
| EP08170260 | 2008-11-28 | ||
| EP09153967 | 2009-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073917A1 true AR073917A1 (es) | 2010-12-09 |
Family
ID=41531663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104058A AR073917A1 (es) | 2008-10-23 | 2009-10-22 | Sinergismo antibiotico |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100104552A1 (es) |
| EP (1) | EP2349318A1 (es) |
| CN (1) | CN102264382A (es) |
| AR (1) | AR073917A1 (es) |
| PA (1) | PA8846401A1 (es) |
| TW (1) | TW201028154A (es) |
| WO (1) | WO2010046462A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0609801B1 (pt) * | 2005-06-06 | 2018-05-29 | Novozymes Adenium Biotech A/S | Polipeptídeo, polinucleotídeo, construção de ácido nucleico, vetor de expressão recombinante,microrganismo recombinante, método para produção do polipeptídeo, composição antimibrobiana, método in vitro para matar ou inibir o crescimento 5 de células microbianas, e, uso de um polipeptídeo antimicrobiano |
| TWI498336B (zh) * | 2012-02-29 | 2015-09-01 | Univ Nat Pingtung Sci & Tech | 用以抑菌之醫藥組合物及其用途 |
| US11060148B2 (en) | 2012-10-16 | 2021-07-13 | Dana-Farber Cancer Institute, Inc. | Diagnosing and treating colorectal cancer |
| JP6457945B2 (ja) | 2012-11-23 | 2019-01-23 | ヘキシマ リミテッドＨｅｘｉｍａ Ｌｉｍｉｔｅｄ | 抗病原体方法 |
| JP2017517498A (ja) * | 2014-04-24 | 2017-06-29 | ヘキシマ リミテッド | 薬剤および治療方法 |
| CN107320727A (zh) * | 2016-04-29 | 2017-11-07 | 四川大学 | 抗菌肽与抗生素组合抗菌药物及其使用方法 |
| EP3809851A4 (en) * | 2018-06-22 | 2022-03-23 | Contrafect Corporation | Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001275208A1 (en) * | 2000-06-01 | 2001-12-11 | University Of Iowa Research Foundation | Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide |
| JP4361796B2 (ja) * | 2001-11-20 | 2009-11-11 | ノボザイムス アクティーゼルスカブ | シュードプレクタニア・ニグレラからの抗菌ポリペプチド |
| US20040194156A1 (en) * | 2002-12-27 | 2004-09-30 | Califa Llc | Transgenic aquatic invertebrates as a bioreactor for production of recombinant polypeptides |
| EP1786453B1 (en) * | 2004-07-22 | 2009-01-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Alpha-defensins as anthrax immunotherapeutics |
| BRPI0609801B1 (pt) * | 2005-06-06 | 2018-05-29 | Novozymes Adenium Biotech A/S | Polipeptídeo, polinucleotídeo, construção de ácido nucleico, vetor de expressão recombinante,microrganismo recombinante, método para produção do polipeptídeo, composição antimibrobiana, método in vitro para matar ou inibir o crescimento 5 de células microbianas, e, uso de um polipeptídeo antimicrobiano |
| JP2009523120A (ja) * | 2005-12-09 | 2009-06-18 | アールエックス３ ファーマシューティカルズ インコーポレイテッド | 抗生物質の相乗効果の同定法と応用法 |
| AU2009231463A1 (en) * | 2008-04-04 | 2009-10-08 | Novozymes Adenium Biotech A/S | Use of defensins against meningitis |
-
2009
- 2009-10-22 PA PA20098846401A patent/PA8846401A1/es unknown
- 2009-10-22 TW TW098135705A patent/TW201028154A/zh unknown
- 2009-10-22 AR ARP090104058A patent/AR073917A1/es not_active Application Discontinuation
- 2009-10-23 EP EP09744372A patent/EP2349318A1/en not_active Withdrawn
- 2009-10-23 CN CN2009801520301A patent/CN102264382A/zh active Pending
- 2009-10-23 US US12/604,440 patent/US20100104552A1/en not_active Abandoned
- 2009-10-23 WO PCT/EP2009/063953 patent/WO2010046462A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2349318A1 (en) | 2011-08-03 |
| CN102264382A (zh) | 2011-11-30 |
| WO2010046462A1 (en) | 2010-04-29 |
| US20100104552A1 (en) | 2010-04-29 |
| TW201028154A (en) | 2010-08-01 |
| PA8846401A1 (es) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073917A1 (es) | Sinergismo antibiotico | |
| BR112013003127A2 (pt) | bismuto-tióis como antissépticos para usos agrícolas, industriais e outros | |
| DOP2020000058A (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas | |
| BRPI0922220B8 (pt) | uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos | |
| BRPI0923326A2 (pt) | Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto. | |
| BR112014024279A8 (pt) | Compostos heterobicíclicos como inibidores de beta-lactamase, composição farmacêutica, uso de um composto | |
| BR112012025844A2 (pt) | uso de nanofibras snag | |
| BR112017027719A2 (pt) | composto, zwitterion, composição farmacêutica, métodos para inibir betalactamase em um indivíduo e para tratamento de uma infecção bacteriana, e, uso de um composto | |
| UA96964C2 (ru) | Соединения полициклической мочевины с антибактериальными свойствами | |
| ATE455786T1 (de) | 6-11 bicyclische ketolidderivate | |
| BR112014023321A2 (pt) | Composições compreendendo fagos antibacterianos e seus usos | |
| BRPI0807487A8 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| BR112015029367A8 (pt) | combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| WO2008036761A3 (en) | Anti-microbial defensin-related peptides and methods of use | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| WO2005070945A8 (ja) | メチシリン耐性黄色ブドウ球菌（ｍｒｓａ）に有効な新規アミノグリコシド系抗生物質 | |
| ZA202309204B (en) | Lactivicin compounds, their preparation and use as antibacterial agents | |
| CL2009000470A1 (es) | Compuestos derivados de 6-oxo-2,3-dihidro-6h-1-oxa-3,3a-diaza-fenaleno sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de infecciones bacterianas, particularmente utiles frente a las bacterias gram (+) y a gram (-), como streptococcus, staphilococcus y escherichia coli, entre otras. | |
| BRPI0607701A2 (pt) | composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto | |
| MX2011002874A (es) | Novedosas formulaciones de carbapenem aminoglicosido como una sola unidad. | |
| WO2009124086A3 (en) | Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections | |
| Barakat et al. | Can Open Fracture Debridement Improve Postoperative Wound Infection?. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |